NCT00542217View on ClinicalTrials.gov

Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

April 30, 2006

Conditions
Healthy
Interventions
BIOLOGICAL

Imprime PGG

Sponsors

Lead Sponsor

HiberCell, Inc.
All Listed Sponsors
lead

HiberCell, Inc.

INDUSTRY

NCT00542217 - Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection | Biotech Hunter | Biotech Hunter